secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-10-05T20:07:45+00:00
Accession:  0001551152-26-000030
Event type: earnings
Sentiment:  negative
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

AbbVie trims 2026 adjusted EPS guidance to $13.76-$13.96 on $216M Q3 IPR&D charge
--------------------------------------------------------------------------------

- Q3 2026 adjusted diluted EPS guidance cut to $3.73-$3.77 from $3.84-$3.88 after $216M pre-tax acquired IPR&D and milestones expense ($0.11/share).
- Full-year 2026 adjusted diluted EPS guidance lowered to $13.76-$13.96 from $13.87-$14.07, reflecting the same $0.11 Q3 impact.
- FY2026 acquired IPR&D and milestones expense now $1,251M versus $1,035M previously announced; AbbVie excludes any beyond-Q3 amounts as not reliably forecastable.
- Results for the quarter ended September 30, 2026 are not finalized and remain subject to financial statement closing procedures; final figures may differ.
- CFO Scott T. Reents signed the October 5, 2026 report; guidance detail is in Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000030/0001551152-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000030/abbv-20261005.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer